Skip to main content

amzeeq

Generic: minocycline·Code: FMX101

amzeeq: sourced relationships with 2 companies · 1 FDA decision.

amzeeq evidence translation

What we can confirm

1 FDA record

What it means

More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

What is verified about amzeeq, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

Inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and olderinflammatory lesions of non-nodular moderate-to-severe acne vulgaris

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
Journey Medical Corp (DERM)
owner · Reported 2024-03-29 · Current development: unknownSource
Inflammatory lesions of non-nodular moderate to severe acne …
Approved
FOAMIX PHARMACEUTICALS LTD. (FOMX)
developer · Reported 2020-03-12 · Current development: unknownSource
inflammatory lesions of non-nodular moderate-to-severe acne …
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE AMZEEQ is indicated for the topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older [ see Clinical Studies ( 14 ) ]. Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, AMZEEQ should be used only as indicated [ see Warnings and Precautions ( 5.14 ) ]. AMZEEQ is a tetracycline-class drug indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. ( 1 ) Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, AMZEEQ should be used only as indicated. ( 5.14 )(DERM)FDA ↗
NDA212379Type 3 - New Dosage FormStandardTopicalAerosol, Foam

Frequently asked questions

Which companies have sourced relationships with amzeeq?

amzeeq has dated SEC/FDA relationship records for Journey Medical Corp, FOAMIX PHARMACEUTICALS LTD..

What is amzeeq's latest FDA decision?

The most recent tracked FDA decision for amzeeq is Approval for 1 INDICATIONS AND USAGE AMZEEQ is indicated for the topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older [ see Clinical Studies ( 14 ) ]. Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, AMZEEQ should be used only as indicated [ see Warnings and Precautions ( 5.14 ) ]. AMZEEQ is a tetracycline-class drug indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. ( 1 ) Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, AMZEEQ should be used only as indicated. ( 5.14 ), dated October 18, 2019.